Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Pharmaceuticals
- Therapeutic
- Drug delivery
- cell therapy
- Diagnostic
- Biotechnology
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28962
License Grant
The Licensor granted rights to C-E Melphalan. This product candidate is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. The Licensee assumed full responsibility for its ongoing clinical and regulatory development program.
IPSCIO Record ID: 332232
License Grant
Licensed Patents. Licensor hereby grants to Licensee an exclusive, nontransferable (except with respect to the assignment provision in this Agreement) license during the Term under the Licensed Patents, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in the Field.
Know-How License Licensor hereby grants to Licensee an exclusive, nontransferable (except with respect to the assignment provision in this Agreement) license during the Term under Licensor’s rights in and to the Captisol Data Package and Product Know-How, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in the Field.
License Property
Captisol means Captisol®, also known scientifically as sulfobutylether ß(beta) cyclodextrin, sodium salt, including all of its optical isomers, and salt, ester, and polymorphic forms.
US Serial Number 12/790,724
Compound means that certain pharmaceutical compound known as melphalan, including all of its optical isomers, and salt, ester, and polymorphic forms.
US Patent #5,376,645 – Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US Patent #7,629,331 – Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US Patent #7,635,773 – Sulfoalkyl ether cyclodextrin compositions
Field of Use
The Captisol-enabled melphalan product candidate is currently in a pivotal trial being conducted by Ligand for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma.
Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by making antibodies that recognize and attack germs. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells.
IPSCIO Record ID: 60409
License Grant
The agreement grants an exclusive license under the patent rights to Captisol relating to the product.
License Property
The related product, Evomela, is a Captisol-enabled melphalan IV formulation. The Evomela formulation avoids the use of propylene glycol, which has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of therapeutic compounds. The use of the Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.
Field of Use
Evomela is intended for use in the multiple myeloma stem cell transplant setting, and has been granted Orphan Designation by the FDA.
IPSCIO Record ID: 26487
License Grant
The Licensor hereby grants to Switzerland company an exclusive (including as to Licensor and its Affiliates) royalty-bearing license to register, distribute, market, use and sell the Products in the Territory under the Licensor'd Patent Rights and the Licensor's Technology.
License Property
Products shall mean each article of manufacture, substance, material, chemical, formulation or composition which is or includes Thalidomide as an active ingredient, including, without limitation, any composition that comprises Thalidomide and a non-steroidal anti-inflammatory compound(s).
The term Products expressly excludes Thalidomide analogs. The product is currently is under review by the European Medicines Agency (EMEA) to treat patients with newly diagnosed multiple myeloma. Multiple myeloma (also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease after Otto Kahler) is a type of cancer of plasma cells which are immune system cells in bone marrow that produce antibodies. Myeloma is regarded as incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants. Myeloma is part of the broad group of diseases called hematological malignancies.
IPSCIO Record ID: 3283
License Grant
The University hereby grants the Licensee an exclusive worldwide right and license in the Licensed field to practice under the Patent Rights and the Technology Rights and to make, have made, use, offer for sale, sell and import Licensed products or the practice of services utilizing the Licensed Processes. Licensee shall have an exclusive option to license any Invention. Licensee
shall have the right to grant sublicenses consistent with this Agreement.
License Property
United States Patent 7,668,659
Diagnosis and classification of multiple myeloma
United States Patent 7,308,364
Diagnosis of multiple myeloma on gene expression profiling
Field of Use
Licensed Field shall mean those applications of Patent Rights and/or the Technology Rights with respect to non-malignant and malignant human or animal pathologies, including but not limited to, determining and/or identifying the presence, predisposition, effect of treatment, mode or type of treatment, type of patient, susceptibility to treatment or prevention, progress of treatment, current and predicted clinical outcome, and/or therapeutic or prophylactic treatment and/or regimen.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
